Recommendation of the President – Bupropion Neuraxpharm (bupropion hydrochloride)
On 17 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 35/2026 regarding the inclusion of the medicinal product Bupropion Neuraxpharm (bupropion hydrochloride) in the reimbursement program for the treatment of major depressive episodes